The Ultrasound Study of Tamoxifen

The Ultrasound Study of Tamoxifen is a 12-month longitudinal study to describe volumetric breast density change over time among women with and without tamoxifen exposure. Women were enrolled at the Karmanos Cancer Institute and Henry Ford Health Systems in Detroit, Michigan between 2011-2014. Enrollment included women prescribed tamoxifen for clinical indication (n=82) and a comparison group of women frequency matched on age, race, and menopausal status (n=165). Whole breast ultrasound tomography (UST) scans were used to measure volume averaged sound speed (m/s) as a surrogate of volumetric breast density. Ultrasound tomography (UST) scans were completed at baseline prior to tamoxifen initiation and were repeated at 1-3 months, 4-6 months, and 12 months after tamoxifen initiation. For the comparison group, UST scans were completed at baseline and 12 months. Questionnaires were completed at each scan. ]]>
Women were eligible if they were aged 30-70 years, weighed ≤350 pounds, had breast size <22 cm in diameter without breast implants, reduction mammoplasty, or active skin infections/open chest wounds, and were not currently pregnant or breastfeeding. Women prescribed tamoxifen for clinical indication included referral from a clinician based on personal breast cancer risk or a diagnosis of incident unilateral invasive, estrogen receptor positive breast cancer, ductal carcinoma in situ, lobular carcinoma in situ, or atypical lobular or ductal hyperplasia. Women eligible for the comparison group presented with a screen negative mammogram and had no history of breast cancer.]]>